Skip to main content
Advances in Preventive Medicine logoLink to Advances in Preventive Medicine
. 2016 Aug 4;2016:9405105. doi: 10.1155/2016/9405105

Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela

Valmore Bermudez 1,*, Juan Salazar 1, María Sofía Martínez 1, Mervin Chávez-Castillo 1, Luis Carlos Olivar 1, María José Calvo 1, Jim Palmar 1, Jordan Bautista 1, Eduardo Ramos 1, Mayela Cabrera 1, Freddy Pachano 2, Joselyn Rojas 1
PMCID: PMC4989131  PMID: 27579182

Abstract

Background and Aim. Insulin resistance (IR) is a prominent pathophysiologic component in a myriad of metabolic disorders, including obesity, prediabetes, and type 2 diabetes mellitus, which are common in our locality. The objective of this study was to determine the prevalence of IR and factors associated with this condition in an adult population from Maracaibo city, Venezuela. Methodology. A cross-sectional, descriptive study with multistaged randomized sampling was carried out in 2026 adults. IR was defined as HOMA2-IR ≥ 2. A multiple logistic regression model was constructed in order to evaluate factors associated with IR. Results. The prevalence of IR was 46.5% (n = 943), with 46.7% (n = 450) in the general population, 46.4% (n = 493) in females, and 47.90% (n = 970) in males (p = 0.895). IR prevalence tended to increase with age and was significantly greater in subjects aged ≥30 years (χ 2 = 16.726; p = 2.33 × 10−4). Employment, alcohol consumption, obesity, high triacylglycerides, low HDL-C, and dysglycemia were associated with greater odds of IR, whereas a high level of physical activity appeared to be weak protective factor against IR. Conclusions. The prevalence of IR is elevated in our locality. The main determinants of this condition appear to be the presence of obesity, high triacylglycerides, low HDL-C, dysglycemia, and alcohol intake.

1. Introduction

The term insulin resistance (IR) was coined in 1936 to describe a metabolic disturbance characterized by decreased cellular responsiveness to insulin signaling in insulin-dependent tissues such as skeletal muscle, liver, and adipose tissue [1]. IR has now been established to play a key role in pancreatic β cell dysfunction and type 2 diabetes mellitus (DM2) [2]. This disease represents one of the leading causes of mortality in the adult population worldwide [3], with alarming projections for the future, with an estimated prevalence of 33% in adults in the USA by 2050 [4]. Furthermore, IR is a fundamental pathophysiologic component of several other endocrine-metabolic disorders, such as hypertension, dyslipidemias, polycystic ovary syndrome, metabolic syndrome, and cardiovascular disease [5, 6].

In light of the great morbidity and mortality rates associated with these disorders, prominent scientific effort has been directed to the refinement of tools for the detection and assessment of IR. In this regard, HOMA2-IR [7] stands as one of the most broadly accepted models in research settings yet remains relatively underutilized in our local clinical scenario. In this context, previous analyses by our research group have estimated specific cutoffs for this variable in our population [8], laying the groundwork for their potential clinical and epidemiologic use.

IR is intimately linked with psychobiologic habits such as smoking, alcohol consumption, hypercaloric diets, and physical inactivity. In turn, these factors can be strongly conditioned by demographic, social, and economic aspects, which shape daily human living. Thus, the objective of this study was to determine the prevalence and determinants of IR in the adult population of Maracaibo city, Venezuela.

2. Materials and Methods

2.1. Sample Selection

This report is part of the Maracaibo City Metabolic Syndrome Prevalence Study, a cross-sectional study whose purpose is to identify MS and cardiovascular risk factors in the adult population of Maracaibo, the second largest city of Venezuela. The sample (1,986 individuals) was calculated based on estimations of the city's population by our National Institute of Statistics (1,428,043 inhabitants for the year 2007). A total of 244 subjects (12%) were added for oversampling, in order to increase accuracy of the estimates obtained from smaller subgroups from the overall sample, amounting to a total of 2,230 individuals. Maracaibo city is divided into parishes, each of which was proportionally sampled with a multistaged cluster method: In the first stage, clusters were represented by sectors from each of the 18 parishes, selecting 4 from each parish by simple randomized sampling. In the second phase, clusters were represented by city blocks within each sector, which were selected by simple randomized sampling using a random number generation tool. Further details of the sampling process have been previously published elsewhere [9].

2.2. Ethical Considerations

All participants signed written consent prior to undergoing physical examination and blood sample collection. All procedures were approved by the Ethics Committee of the Endocrine and Metabolic Diseases Research Center of The University of Zulia, Maracaibo, Venezuela.

2.3. Subject Evaluation

Data were collected through completion of a full clinical record carried out by trained personnel, which encompassed interrogation regarding ethnic origin, marital status (single, married, cohabiting, or divorced), occupational status (employed or unemployed), and educational status, under the following definitions: (a) illiterate, subjects with no reading or writing skills; (b) primary education, those who attended or finished primary or middle school; (c) secondary education, those who attended or finished high school; and (d) high education, those who attended or finished college/university [9]. Socioeconomic status was assessed with the Graffar scale modified by Méndez-Castellano for the Venezuelan population [10]. This tool allows stratification of the population according to four variables: occupation of the head of household, educational level of the subject's parents, income source, and housing conditions. Each of these items is rated in a Likert-type scale from 1 to 5 (1 representing the best possible scenarios and 5 the worst). The scores for each item are tallied into a total integrated score ranging from 4 to 20 points, categorized as follows: Stratum I or High Class (4–6 points); Stratum II or Middle-High Class (7–9 points); Stratum III or Middle Class (10–12 points); Stratum IV or Relative Poverty (13–16 points), and Stratum V or Critical Poverty (17–20 points).

2.3.1. Smoking Habit

Based on information obtained during the clinical interview, subjects were categorized by their smoking habits as follows [11]: (a) nonsmokers, individuals who had never smoked or had smoked <100 cigarettes in their lifetime; (b) current smokers, subjects who had smoked ≥100 cigarettes in their lifetime or reported current habitual smoking at the time of evaluation or had quit smoking less than one year prior to our assessment; and (c) past smokers, individuals who had consumed ≥100 cigarettes in their lifetime and quit over one year prior to our questioning.

2.3.2. Alcohol Consumption

For the assessment of alcohol intake, subjects were asked to estimate the amount of alcoholic drinks they consumed within a month, with the approximate quantity and frequency of daily intake for each type of drink: beer, spirits, and wine and its derivatives. Accounting for the standard content of alcohol grams in each kind of beverage [12], daily intake of alcohol grams was calculated through the following formula [13]:

Daily consumed (mL)×degrees of alcohol×0.8100, (1)

where 0.8 is a constant representing ethanol density in drinks. Based on this estimation, drinkers were defined as subjects who consumed ≥1 gram of alcohol daily [14].

2.3.3. Physical Activity

Physical activity (PA) was assessed with the International Physical Activity Questionnaire (IPAQ) [15]. For statistical analysis, PA was evaluated in 4 domains: occupational, household, transport, and leisure. In each of these domains, subjects were categorized as follows: (a) inactive, MET/week = 0, or (b) active, MET/week >0. The latter were then subcategorized by gender-specific MET/week quintiles in each domain (Table 1).

Table 1.

Gender-specific MET quintiles for each domain of physical activity (Maracaibo, Venezuela, 2015).

MET quintiles  Females  Males
Work
domain
Lower limit Upper limit Lower limit Upper limit

Very low 33.00 385.99 33.00 714.99
Low 386.00 1201.49 715.00 2042.09
Moderate 1201.50 2751.59 2042.10 3578.39
High 2751.60 4546.79 3578.40 6495.59
Very high 4546.80 4546.80

Transport
domain
Lower limit Upper limit Lower limit Upper limit

Very low 33.00 131.99 33.00 164.99
Low 132.00 230.99 165.00 257.49
Moderate 231.50 346.49 247.50 521.09
High 346.50 700.79 521.10 1385.99
Very high 700.80 1386.00

Household
domain
Lower limit Upper limit Lower limit Upper limit

Very low 30.00 539.99 30.00 269.99
Low 540.00 1139.99 270.00 629.99
Moderate 1140.00 1919.99 630.00 1084.99
High 1920.00 3779.99 1085.00 2429.99
Very high 3780.00 2430.00

Leisure
domain
Lower limit Upper limit Lower limit Upper limit

Very low 33.00 230.99 33.00 296.99
Low 321.00 445.49 297.00 791.99
Moderate 445.50 742.49 792.00 1532.39
High 742.50 1798.79 1532.40 2879.99
Very high 1798.80 2880.00

Obtained from IPAQ scoring. Subjects with 0 MET were excluded from quintiles and classified separately as inactive.

2.3.4. Blood Pressure

Blood pressure (BP) was taken with subjects sitting down with their feet on the floor following 15 minutes of rest, determined through the auscultatory method with a calibrated mercury sphygmomanometer, identifying Korotkoff's phases I and V as systolic and diastolic BP, respectively. BP was determined 3 times, with 15 minutes in between each take, on two different days; results were classified by the Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-8) guidelines [16].

2.3.5. Anthropometry

An electrical bioelectric scale was used to obtain weight (Tanita, TBF-310 GS Body Composition Analyzer, Tokyo, Japan). Height was measured using a calibrated metric measurement tape, with the subject standing up barefoot. Body Mass Index (BMI) was calculated with the following formula: [weight/height2] expressing results as kg/m2. According to their BMI, subjects were sorted in 3 categories: (a) BMI ≤ 24.9; (b) 25–29.9; and (c) ≥30 [17]. Waist circumference (WC) was evaluated with calibrated measuring tapes in accordance with the anatomical landmarks proposed by the USA National Institutes of Health protocol [18].

2.3.6. Laboratory Analysis

Overnight fasting determination of glucose, total cholesterol, triacylglycerides (TAG), and HDL-C was done with an automated analyzer (Human Gesellschaft für Biochemica und Diagnostica mbH, Germany); the intra-assay variation coefficients for total cholesterol, TAG, and HDL-C were 3%, 5%, and 5%, respectively. LDL-C and VLDL-C levels were calculated applying Friedewald's formula [19] but when TAG levels were <400 mg/dL. LDL-C concentrations were directly measured through lipoprotein electrophoresis and densitometry with a BioRad GS-800 optical densitometer. Insulin was quantified using ultrasensitive ELISA double-sandwich methodology (DRG Instruments GmbH, Germany, Inc.).

2.3.7. Diagnosis of Metabolic Syndrome

The metabolic syndrome was defined by the criteria from the IDF/NHLBI/AHA/WHF/IAS/IASO-2009 consensus [20], which require the presence of ≥3 of the following components: (a) low HDL-C, <50 mg/dL in females or <40 mg/dL in males; (b) high TAG, ≥150 mg/dL; (c) elevated WC, ≥80 cm in females or ≥90 cm in males; (d) hyperglycemia, fasting glycemia ≥100 mg/dL or personal history of type 2 diabetes mellitus or prescription of hypoglycemic drugs; and (e) High Blood Pressure, BP ≥130/85 mm/Hg or previously diagnosed hypertension or prescription of antihypertensive drugs.

2.3.8. Assessment of Insulin Resistance

HOMA2-IR was utilized for the evaluation of IR as proposed by Levy et al. [21], computed with the HOMA-Calculator version 2.2.2 software application. IR was defined as HOMA2-IR ≥ 2 [8].

2.4. Statistical Analysis

Qualitative variables were expressed as absolute and relative frequencies, evaluating association through Pearson's Chi-squared (χ 2) test, while the Z test for proportions was used to assess differences between proportions. Quantitative variables were evaluated for distribution normality with Geary's test and were expressed as arithmetic means ± SD. Variables with nonnormal distribution underwent logarithmic transformation; when normalization could not be achieved, these variables were expressed as medians (25th percentile–75th percentile). Student's t-test or Mann-Whitney's U tests were applied to evaluate differences between means or medians, respectively.

A multiple logistic regression model was constructed in order to estimate odds ratios (confidence interval 95%) for the presence of IR, adjusted by gender, age groups, ethnic groups, socioeconomic status, educational status, marital status, occupational status, smoking habits, leisure-domain PA, glycemic status, presence of high TAG, presence of low HDL-C, JNC-8 classification, presence of elevated WC, and BMI classification. Data were analyzed with the Statistical Package for the Social Sciences (SPSS) version 21 for Windows (IBM Inc., Chicago, IL), and the results were considered statistically significant when p < 0.05.

3. Results

3.1. Characteristics of the General Population

The sociodemographic and psychobiologic features of the sample are summarized in Table 2, while metabolic and anthropometric aspects are presented in Table 3. A total of 2026 individuals were studied: 52.10% (n = 1056) females and 47.90% (n = 970) males. The mean age was 39.69 ± 15.37 years (41.06 ± 15.68 years for women, 38.20 ± 14.89 years for men).

Table 2.

Sociodemographic and psychobiologic characteristics of the population by gender (Maracaibo, Venezuela, 2015).

 Females (n = 1056)  Males (n = 970)  Total (n = 2026)
n % n % n %
Age groups (years)
 <30 308 29.2 365 37.6 673 33.2
 30–59 607 57.5 517 53.3 1124 55.5
 ≥60 141 13.4 88 9.1 229 11.3

Ethnic groups
 Mixed 796 75.4 754 77.7 1550 76.5
 Hispanic white 175 16.6 146 15.1 321 15.8
 Afro-Venezuelan 27 2.6 33 3.4 60 3.0
 American Indian 47 4.5 36 3.7 83 4.1
 Others 11 1.0 1 0.1 12 0.6

Socioeconomic status
 Stratum I 17 1.6 19 2.0 36 1.8
 Stratum II 179 17.0 185 19.1 364 18.0
 Stratum III 394 37.3 409 42.2 803 39.6
 Stratum IV 411 38.9 325 33.5 736 36.3
 Stratum V 55 5.2 32 3.3 87 4.3

Marital status
 Single 445 42.3 414 43.1 859 42.7
 Married 392 37.2 417 43.4 809 40.2
 Others 216 20.5 130 13.5 346 17.2

Educational status
 Illiterate 25 2.4 17 1.8 42 2.1
 Primary education 217 20.5 103 10.6 320 15.8
 Secondary education 466 44.1 479 49.4 945 46.6
 High education 348 33.0 371 38.2 719 35.5

Occupational status
 Unemployed 575 54.5 263 27.1 838 41.4
 Employed 481 45.5 707 72.9 1188 58.6

Smoking habit
 Nonsmoker 792 75.1 606 62.9 1398 69.3
 Current smoker 119 11.3 181 18.8 300 14.9
 Past smoker 143 13.6 177 18.4 320 15.9

Alcohol intake (%) 196 18.6 470 48.5 666 32.9

Physical inactivity ∗∗ (%) 252 23.9 443 45.7 695 34.3

≥1 g of alcohol per day. ∗∗Based on IPAQ scoring.

Table 3.

Anthropometric and cardiometabolic characteristics of the population by gender (Maracaibo, Venezuela, 2015).

 Females (n = 1056)  Males (n = 970)  Total (n = 2026)
n % n % n %
Body Mass Index (kg/m 2)
 ≤24.9 377 35.7 245 25.3 622 30.7
 25–29.9 333 31.5 386 39.8 719 35.5
 ≥30 346 32.8 339 34.9 685 33.8

High TAG
 Absent 815 77.2 644 66.4 1459 72.0
 Present 241 22.8 326 33.6 567 28.0

Low HDL-C
 Absent 384 36.4 479 49.4 863 42.6
 Present 672 63.6 491 50.6 1163 57.4

Elevated WC
 Absent 597 51.0 502 47.4 1099 49.3
 Present 573 49.0 556 52.6 1129 50.7

JNC-8 classification
 Normotensive 481 45.5 312 32.2 793 39.1
 Prehypertensive 381 36.1 384 39.6 765 37.8
 Hypertensive 194 18.4 274 28.2 468 23.1

Glycemic status ¥
 Normoglycemic 775 73.5 667 68.8 1442 71.2
 Impaired fasting glycemia 187 17.7 217 22.4 404 20.0
 Type 2 diabetes mellitus 92 8.7 86 8.9 178 8.8

TAG: triacylglycerides; HDL-C: high-density lipoprotein-cholesterol; WC: waist circumference.

IDF/AHA/NHLBI/WHF/IAS/IASO 2009 consensus criteria.

Females ≥ 90 cm; males ≥ 95 cm.

¥ ADA 2014 classification.

3.2. HOMA2-IR by Gender and Age Groups

The prevalence of IR was 46.5% (n = 943) in the general population, with 46.7% (n = 493) in women and 46.4% (n = 450) in men (χ 2 = 0.018; p = 0.895) (Figure 1(a)). On the other hand, Figure 1(b) illustrates the prevalence of IR by age groups: A significantly greater proportion of IR was found in the groups aged 30–59 years (49.7%, n = 559) and ≥60 years (49.8%, n = 114), in comparison to individuals aged <30 years (40.1%, n = 270) (χ 2 = 16.726; p = 2.33 × 10−4).

Figure 1.

Figure 1

Prevalence of insulin resistance by gender and age groups. Maracaibo, Venezuela. 2014. Z Test for proportions: gender: nonsignificant. Age groups: <30 years (HOMA2-IR < 2 versus HOMA2-IR ≥ 2; p < 0.05); 30–59 years (HOMA2-IR ≥ 2 versus HOMA2-IR < 2; p < 0.05).

3.3. HOMA2-IR and Other Sociodemographic Factors

When assessing the epidemiologic behavior of IR according to sociodemographic factors (Table 4), an association was found only in regard to marital status (χ 2 = 17.293, p = 0.001), with a significantly greater proportion of IR subjects among married individuals (51.5% versus 48.5% individuals with HOMA2-IR < 2).

Table 4.

Prevalence of insulin resistance in the general population by sociodemographic variables (Maracaibo, Venezuela, 2015).

 HOMA2-IR < 2  HOMA2-IR ≥ 2 p χ 2(p)
n % n %
Ethnic group 2.65 (0.61)
 Mixed 837 54.0 713 46.0 NS
 Hispanic white 161 50.2 160 49.8 NS
 Afro-Venezuelan 33 55.0 27 45.0 NS
 American Indian 47 56.6 36 43.4 NS
 Others 5 41.7 7 58.3 NS

Socioeconomic status 4.33 (0.36)
 Stratum I: High Class 18 50.0 18 50.0 NS
 Stratum II: Middle-High Class 186 51.1 178 48.9 NS
 Stratum III: Middle Class 445 55.4 358 44.6 NS
 Stratum IV: Relative Poverty 382 51.9 354 48.1 NS
 Stratum V: Critical Poverty 52 59.8 35 40.2 NS

Marital status 17.29 (0.001)
 Single 503 58.6 356 41.4 <0.05
 Married 392 48.5 417 51.5 <0.05
 Others 181 52.3 165 47.7 NS

Educational status 6.76 (0.079)
 Illiterate 27 64.3 15 35.7 NS
 Primary education 154 48.1 166 51.9 <0.05
 Secondary education 521 55.1 424 44.9 NS
 High education 381 53.0 338 47.0 NS

Occupational status 3.25 (0.071)
 Unemployed 428 51.1 410 48,9 NS
 Employed 655 55.1 533 44.9 NS

NS: nonsignificant; p : Z test for proportions; χ 2: Pearson's Chi-squared test.

3.4. HOMA2-IR and Psychobiologic Habits

Regarding smoking habits (Figure 2(a)), no link was found with the presence of IR (χ 2 = 6.575; p = 0.37). Nevertheless, we observed a greater proportion of IR subjects among past smokers (51.9% versus 48.1% without IR; p < 0.05). Conversely, the absence of IR was prevalent among nonsmokers (55.2% versus 44.8% with IR; p < 0.05). With respect to alcohol intake and IR (Figure 2(b)), no statistically significant association was found (χ 2 = 3.969; p = 0.46). Similarly, no link was ascertained between IR and PA in the home (χ 2 = 2.27; p = 0.81), work (χ 2 = 1.82; p = 0.87), and transport (χ 2 = 8.60; p = 0.12) domains (Table 5). However, a significant association was ascertained between the presence of IR and leisure-domain PA (χ 2 = 23.24;  p = 0.003), with a higher proportion of non-IR individuals in the high and very high PA categories in this domain (61.3%, n = 92 and 65.5%, n = 110, resp., versus IR subjects; p < 0.05).

Figure 2.

Figure 2

Prevalence of insulin resistance in the general population by smoking habits and alcohol intake. Maracaibo, Venezuela. 2014. χ 2 = Pearson's Chi-squared test. Z test for proportions: smoking habits: nonsmokers (HOMA2-IR < 2 versus HOMA2-IR ≥ 2; p < 0.05); past smokers (HOMA2-IR ≥ 2 versus HOMA2-IR < 2; p < 0.05). Alcohol intake: present (HOMA2-IR ≥ 2 versus HOMA2-IR < 2; p < 0.05); absent (HOMA2-IR < 2 versus HOMA2-IR ≥ 2; p < 0.05).

Table 5.

Prevalence of insulin resistance in the general population by physical activity domains (Maracaibo, Venezuela, 2015).

Physical activity pattern  HOMA2-IR < 2  HOMA2-IR ≥ 2 p χ 2(p)
n % n %
Work domain 1.82 (0.87)
 Inactive 799 53.1 706 46.9 NS
 Very low 56 53.8 48 46.2 NS
 Low 63 58.9 44 41.1 NS
 Moderate 52 51.0 50 49.0 NS
 High 54 52.9 48 47.1 NS
 Very high 59 55.7 47 44.3 NS

Transport domain 8.60 (0.12)
 Inactive 359 49.3 369 50.7 NS
 Very low 129 56.3 100 43.7 NS
 Low 147 56.1 115 43.9 NS
 Moderate 142 55.5 114 44.5 NS
 High 161 57.1 121 42.9 NS
 Very high 132 54.8 109 45.2 NS

Household domain 2.27 (0.81)
 Inactive 295 52.2 270 47.8 NS
 Very low 151 55.7 120 44.3 NS
 Low 160 53.5 139 46.5 NS
 Moderate 172 56.2 134 43.8 NS
 High 148 52.5 134 47.5 NS
 Very high 157 51.8 146 48.2 NS

Leisure domain 23.24 (0.003)
 Inactive 612 50.0 613 50.0 NS
 Very low 79 50.3 78 49.7 NS
 Low 98 57.6 72 42.4 NS
 Moderate 92 59.0 64 41.0 NS
 High 92 61.3 58 38.7 <0.05
 Very high 110 65.5 58 34.5 <0.05

NS: nonsignificant; χ 2: Pearson's Chi-squared test; p : Z test for proportions.

3.5. HOMA2-IR and Metabolic Characteristics

The presence of HOMA2-IR ≥ 2 was found to be associated with various metabolic characteristics (Table 6), being significantly more prevalent among subjects with BMI ≥ 30 kg/m2 (68.8% versus 31.2% in subjects without IR; p < 0.05), high TAG (62.8% versus 37.2%; p < 0.05), low HDL-C (52.5% versus 47.5%; p < 0.05), elevated WC (67.7% versus 36.3%; p < 0.05), hypertension (57.9% versus 42.1%; p < 0.05), impaired fasting glucose (37.6% versus 62.4%; p < 0.05), and DM2 (78.7% versus 21.3%; p < 0.05).

Table 6.

Prevalence of insulin resistance in the general population by metabolic characteristics (Maracaibo, Venezuela, 2015).

 HOMA2-IR < 2  HOMA2-IR ≥ 2 p χ 2(p)
n % n %
Body Mass Index (kg/m 2) 232.022 (<0.001)
 ≤24.9 456 73.3 166 26.7 <0.05
 25–29.9 409 57.4 305 42.6 <0.05
 ≥30 214 31.2 469 68.8 <0.05

High TAG 83.47 (5.42 × 10 20)
 Absent 872 59.8 587 40.2 <0.05
 Present 211 37.2 356 62.8 <0.05

Low HDL-C 38.27 (6.15 × 10 10)
 Absent 530 61.4 333 38.6 <0.05
 Present 553 47.5 610 52.5 <0.05

Elevated WC 198.75 (<0.001)
 Absent 689 63.7 304 32.3 <0.05
 Present 393 36.3 638 67.7 <0.05

JNC-8 classification 42.83 (<0.001)
 Normotensive 484 61 309 39 <0.05
 Prehypertensive 402 52.5 363 47.5 NS
 Hypertensive 197 42.1 271 57.9 <0.05

Glycemic status ¥ 155.37 (<0.001)
 Normoglycemic 892 61.9 550 38.1 <0.05
 Impaired fasting glycemia 152 37.6 252 62.4 <0.05
 Type 2 diabetes mellitus 38 21.3 140 78.7 <0.05

Z test for proportions; χ 2: Pearson's Chi-squared test.

TAG: triacylglycerides; HDL-C: high-density lipoprotein-cholesterol; WC: waist circumference.

IDF/AHA/NHLBI/WHF/IAS/IASO 2009 consensus criteria.

Females ≥ 90 cm; males ≥ 95 cm.

¥ ADA 2014 classification.

3.6. HOMA2-IR and Biologic and Anthropometric Variables

Table 7 displays the behavior of several biologic and anthropometric characteristics by IR status. Individuals with this disorder had significantly higher age (p = 3.15 × 10−5), BMI (p = 13 × 10−5), WC (p = 4.49 × 10−54), fasting blood glucose (p = 3.41 × 10−39), systolic BP (p = 2.33 × 10−8), diastolic BP (p = 2.93 × 10−11), and hs-CRP (p = 4.51 × 10−7) than the non-IR population. A similar pattern was found regarding serum lipids, especially TAG (154.48 ± 122.02 versus 110.70 ± 76.27; IR and non-IR subjects, p = 5.45 × 10−29) and HDL-C, which was significantly lower in IR individuals (41.97 ± 10.95 versus 45.90 ± 12.58; p = 3.67 × 10−14).

Table 7.

Biologic and anthropometric characteristics in the general population by insulin resistance status (Maracaibo, Venezuela, 2015).

HOMA2-IR < 2 (n = 1083) HOMA2-IR ≥ 2 (n = 943) p
Age (years)a 38.48 ± 15.50 41.09 ± 15.11 3.15 × 10−5
Body Mass Index (kg/m2)a 26.39 ± 5.24 30.60 ± 6.52 7.13 × 10−55
Waist circumference (cm)a 89.92 ± 12.68 100.34 ± 16.6 4.49 × 10−54
Fasting glycemia (mg/dL)a 91.88 ± 20.99 107.48 ± 50.78 3.41 × 10−39
Fasting insulin (µU/mL)a 8.80 ± 2.70 21.46 ± 10.15 <0.001
HOMA2-IRa 1.31 ± 0.40 3.24 ± 1.47 <0.001
Total cholesterol (mg/dL)a 186.91 ± 45.67 196.87 ± 46.31 2.39 × 10−7
Triacylglycerides (mg/dL)a 110.70 ± 76.27 154.48 ± 122.02 5.45 × 10−29
LDL-C (mg/dL)a 118.80 ± 38.06 125.25 ± 38.84 <0.001
HDL-C (mg/dL)a 45.90 ± 12.58 41.97 ± 10.95 3.67 × 10−14
Systolic BP (mmHg)a 117.91 ± 16.57 121.96 ± 17.08 2.33 × 10−8
Diastolic BP (mmHg)a 75.75 ± 10.99 79.05 ± 11.44 2.93 × 10−11
hs-CRP (mg/dL)b 0.313 (0.086–0.622) 0.420 (0.154–0.942) 4.51 × 10−7

LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol; BP: blood pressure; hs-CRP: High-Sensitivity C-Reactive Protein.

aNormally distributed variable, expressed as mean ± standard deviation; bnonnormally distributed variable, expressed as median (25th percentile–75th percentile).

Student's t-test was used for normally distributed variables; Mann-Whitney U test was used for nonnormally distributed variables.

3.7. Risk Factors for Insulin Resistance in Maracaibo City

The risk factors for the presence of IR in our population are shown in Table 8. Following adjustment of the multivariate model, the age groups of 30–59 years (OR: 0.65, CI 95%: 0.50–0.85; p < 0.01) and ≥60 years (OR: 0.42, CI 95%: 0.28–0.65; p < 0.01) were associated with lower odds of IR. On the other hand, the female gender (OR: 1.29, CI 95%: 1.02–1.65; p = 0.04) and employed occupational status (OR: 1.45, CI 95%: 1.15–1.83; p < 0.01) were linked with higher risk of IR. The sole psychobiologic factor independently related to IR was alcohol intake (OR: 1.41, CI 95%: 1.10–1.79; p < 0.01). Similarly, high TAG (OR: 1.77, CI 95%: 1.38–2.27; p < 0.01), low HDL-C (OR: 1.31, CI 95%: 1.06–1.64; p = 0.01), and BMI ≥30 kg/m2 (OR: 4.33, CI 95%: 2.97–6.29; p < 0.01), as well as impaired fasting glucose and DM2, were also associated with increased odds of IR in our population. Furthermore, no relevant differences were revealed after adjustment of a second model with exclusion of diabetic subjects.

Table 8.

Sociodemographic and metabolic risk factors associated with insulin resistance (Maracaibo, Venezuela, 2015).

Model 1 Model 2
Crude odds ratio
(CI 95%a)
p b Adjusted odds ratio
(CI 95%a)
p b Adjusted odds ratio
(CI 95%a)
p b
Gender
 Males 1.00 1.00 1.00
 Females 1.01 (0.85–1.21) 0.89 1.29 (1.02–1.65) 0.04 1.33 (1.04–1.71) 0.02

Age groups (years)
 <30 1.00 1.00 1.00
 30–59 1.48 (1.22–1.80) <0.01 0.65 (0.50–0.85) <0.01 0.64 (0.49–0.84) <0.01
 ≥60 1.50 (1.11–2.02) <0.01 0.42 (0.28–0.65) <0.01 0.42 (0.27–0.66) <0.01

Occupational status
 Unemployed 1.00 1.00 1.00
 Employed 1.31 (1.09–1.58) <0.01 1.45 (1.15–1.83) <0.01 1.42 (1.12–1.80) <0.01

Leisure-domain physical activity
 Inactive 1.00 1.00 1.00
 Very low 0.99 (0.71–1.37) 0.93 1.25 (0.85–1.86) 0.24 1.29 (0.87–1.93) 0.21
 Low 0.73 (0.53–1.01) 0.06 0.71 (0.48–1.04) 0.07 0.70 (0.47–1.04) 0.08
 Moderate 0.69 (0.49–0.97) 0.04 0.76 (0.51–1.14) 0.17 0.72 (0.48–1.09) 0.12
 High 0.63 (0.45–0.89) <0.01 0.69 (0.46–1.03) 0.07 0.63 (0.41–0.95) 0.03
 Very high 0.53 (0.38–0.74) <0.01 0.77 (0.52–1.15) 0.19 0.80 (0.54–1.20) 0.28

Alcohol intake
 Absent 1.00 1.00 1.00
 Present 1.21 (1.00–1.47) 0.05 1.41 (1.10–1.79) <0.01 1.44 (1.12–1.84) <0.01

High TAG
 Absent 1.00 1.00 1.00
 Present 2.51 (2.05–3.06) <0.01 1.77 (1.38–2.27) <0.01 1.76 (1.36–2.29) <0.01

Low HDL-C
 Absent 1.00 1.00 1.00
 Present 1.76 (1.47–2.10) <0.01 1.31 (1.06–1.64) 0.01 1.33 (1.06–1.66) 0.01

Elevated waist circumference
 Absent 1.00 1.00 1.00
 Present 3.68 (3.06–4.42) <0.01 1.31 (0.98–1.76) 0.07 1.28 (0.95–1.73) 0.11

JNC-8 classification
 Normotensive 1.00 1.00 1.00
 Prehypertensive 1.41 (1.16–1.73) <0.01 0.96 (0.75–1.22) 0.73 0.96 (0.75–1.23) 0.75
 Hypertensive 2.16 (1.71–2.72) <0.01 0.99 (0.73–1.37) 0.99 1.06 (0.77–1.46) 0.73

Body Mass Index (kg/m 2)
 ≤24.9 1.00 1.00 1.00
 25–29.9 2.04 (1.62–2.57) <0.01 1.90 (1.41–2.55) <0.01 1.93 (1.43–2.61) <0.01
 ≥30 6.05 (4.76–7.69) <0.01 4.33 (2.97–6.29) <0.01 4.40 (2.99–6.47) <0.01

Glycemic status ¥
 Normoglycemic 1.00 1.00 1.00
 Impaired fasting glycemia 2.69 (2.14–3.38) <0.01 2.43 (1.87–3.15) <0.01 2.44 (1.88–3.17) <0.01
 Type 2 diabetes mellitus 5.98 (4.11–8.68) <0.01 4.62 (2.71–7.88) <0.01

aConfidence interval (95%); bsignificance.

Model 1: adjusted for gender, age groups, ethnic groups, socioeconomic status, educational status, marital status, occupational status, diabetes mellitus family history, alcohol intake, smoking habits, leisure-domain physical activity, glycemic status, presence of high TAG, low HDL-C, and elevated waist circumference, BMI classification and JNC-8 classification.

Model 2: excluding diabetic subjects.

¥ ADA 2014 classification.

IDF/AHA/NHLBI/WHF/IAS/IASO 2009 consensus criteria.

4. Discussion

In recent years, a myriad of biologic, psychological, sociodemographic, and economic factors have driven the epidemiologic transition, which features a shift in the major worldwide causes of mortality from infectious diseases to chronic-degenerative disorders [22]. This group includes cardiovascular disease and DM2, where IR plays a fundamental role in their pathophysiology, in close association with Westernized lifestyles such as physical inactivity and hypercaloric diets [1]. Thus, detection and management of this condition have become a priority in primary care. Nevertheless, its epidemiologic behavior remains incompletely elucidated in many populations, including our locality.

We found the prevalence of IR in Maracaibo to be relatively elevated, in harmony with other reports within our country, 54.8% in Valencia city [23], 50.6% in a community from Tinaquillo [24], and up to 61.2% in a Canarian-Venezuelan population [25]. This may be explained by the growing prevalence of obesity and other cardiovascular risk factors in Venezuela [26], as well as methodological limitations and heterogeneity.

Moreover, IR prevalence is widely variable across demographics: whereas European populations appear to boast lower prevalence of IR, estimated at 17% in a Danish study, for example, [27], it has been reported to be as high as 51% in Iran, West Asia [28]. On the other hand, IR prevalence has been estimated at 39.1% in Hispanic subjects residing in Texas, USA [29]. Indeed, differing genetic, epigenetic, and sociocultural factors are important determinants of insulin sensitivity [30, 31]. In addition, utilization of IR-assessing methods different from HOMA2-IR or arbitrary cutoffs may also contribute to these disparities [32].

In our sample, IR prevalence was similar between genders, diverging from findings in a Danish population [27] and the Framingham Heart Study [33], where men showed a higher prevalence, ostensibly attributed to the protective role of estrogens in the development of IR [34]. However, in our study, multivariate analysis revealed women to be at greater risk of IR, echoing a previous report by Rojas et al. [35] on subjects with acute coronary syndrome from Maracaibo. Furthermore, it should be noted that, in this study, the average age in females was 41 years, when a progressive decline in ovarian function tends to begin in most women [36]. In addition, females older than this average age displayed greater prevalence of DM2 and physical inactivity than their male counterparts; these factors favor endocrine-metabolic aging [37] which may explain our findings.

Indeed, aging has been closely linked with IR, chiefly due to the loss of lean mass and gain of visceral adiposity seen in this process [38]. Nonetheless, in multivariate analysis, we found individuals aged ≥60 years to have lower odds of IR. In this regard, certain reports have outlined a protective or innocuous role for adiposity in old age, due to reduced lipolytic activity in this tissue [39]. Likewise, in subjects with chronic-degenerative diseases, a BMI ≥ 25 Kg/m2 has been reported to be linked with lower mortality, in a phenomenon termed the “obesity paradox” [40, 41]. This effect may be responsible for the lower prevalence of IR in our study, as subjects aged ≥60 years exhibited high prevalence of abdominal obesity and comorbidities such as DM2, metabolic syndrome, and hypertension. At any rate, this relationship is very complex with numerous confounding factors, for example, smoking habits, and other comorbidities; therefore, future studies should further explore the interplay between obesity, IR, and old age.

When examining sociodemographic factors, we found marital status to be associated with IR, which was more frequent among married subjects. Notably, a large part of these were male, were inactive, and had elevated BMI and WC, possibly underlying this epidemiologic behavior. This harmonizes with the research by Sobal et al. [42] and Kiadaliri et al. [43] who described married men to have increased risk of overweight and obesity, associated with more frequent and abundant eating and decreased PA. Occupational status also displayed an interesting relationship with IR in our study, with employed individuals having increased odds for this condition. In this context, unemployed subjects exhibited higher leisure-domain PA, along with lower prevalence of elevated WC than their counterparts, in consonance with findings in an Iranian population where unemployment was a protective factor against overweight and obesity [43].

On the other hand, performance of any degree of leisure-domain PA, even under the recommended threshold, has been described to reduce global, cardiovascular, and cancer-related mortality [44], accompanied by a favorable impact on insulin sensitivity and glucose tolerance [45]. We found leisure-domain PA to be a protective factor against IR in males with >297 MET/week and females with >231 MET/week; thus, the American Diabetes Association recommendations on PA intensity and quantity may be applicable for prevention of DM2 in Maracaibo [46].

Alcohol consumption was found to be another risk factor for IR in our population. In a previous publication [14], we reported 45% of men and 16.7% of women in Maracaibo to be habitual drinkers; of these, 72.4% and 76.2% were shown to drink approximately 1–4 beers daily with a high prevalence of abdominal obesity in this group. In this respect, a meta-analysis by Bendsen et al. [47] encompassing 35 observational studies and 12 experimental studies determined high beer intake (>500 mL/day) to be associated with abdominal obesity, which in turn plays a central role in the development of IR.

We also found each of the separate components of the metabolic syndrome to be independently associated with IR, with the exception of hypertension. The relationship with obesity appears most prominent: In our population, BMI ≥ 30 kg/m2 grants 4 times greater odds of IR; this link has been extensively demonstrated in several cross-sectional and longitudinal studies [48, 49]. Similarly, high TAG has been associated with decreased insulin sensitivity [50], and both this disorder and low HDL-C have been independently linked with IR [51]. However, in our population, the mild association between elevated WC and IR appears to be dependent on the presence of DM2.

As may be expected, we also found high odds of IR in subjects with hyperglycemia; in this state, oxidation of fatty acids is attenuated, favoring their esterification and leading to a subsequent increase in synthesis of adipokines, which disrupt insulin activity and peripheral utilization of glucose [52]. In parallel, hyperglycemia potentiates oxidative stress via activation of the ceramide and diacylglycerol pathways and other intermediaries, which also hinder insulin signaling [53].

Our results show a close relationship between IR and various sociodemographic, psychobiologic, and cardiometabolic factors in our population, highlighting the clinician's role in the early detection of this condition. Indeed, regardless of the methods employed [54], identification of subjects at high cardiometabolic risk is a fundamental preventive strategy for reducing the morbidity and mortality of disorders associated with IR.

Acknowledgments

This work was supported by Research Grant no. CC-0437-10-21-09-10 from Consejo de Desarrollo Científico, Humanístico y Tecnológico (CONDES), University of Zulia, and Research Grant no. FZ-0058-2007 from Fundacite-Zulia.

Competing Interests

The authors have are no conflict of interests to disclose.

References

  • 1.Kasuga M. Insulin resistance and pancreatic β cell failure. Journal of Clinical Investigation. 2006;116(7):1756–1760. doi: 10.1172/JCI29189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Costes S., Langen R., Gurlo T., Matveyenko A. V., Butler P. C. β-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes. 2013;62(2):327–335. doi: 10.2337/db12-1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.World Health Organization. The top ten causes of death. Fact Sheet No. 2011;(310) http://www.who.int/mediacentre/factsheets/fs310/en/
  • 4.Boyle J. P., Thompson T. J., Gregg E. W., Barker L. E., Williamson D. F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics. 2010;8:p. 29. doi: 10.1186/1478-7954-8-29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Serrano Ríos M. Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2. Medicina Clínica. 2002;119(12):458–463. doi: 10.1016/S0025-7753(02)73455-6. [DOI] [PubMed] [Google Scholar]
  • 6.Rojas J., Bermúdez V., Leal E., et al. Insulinorresistencia e hiperinsulinemia como factores de riesgo para enfermedad cardiovascular. Archivos Venezolanos de Farmacología y Terapéutica. 2008;27(1):29–39. [Google Scholar]
  • 7.Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi: 10.1007/bf00280883. [DOI] [PubMed] [Google Scholar]
  • 8.Bermúdez V., Rojas J., Martínez M. S., et al. Epidemiologic behavior and estimation of an optimal cut-off point for homeostasis model assessment-2 insulin resistance: a report from a Venezuelan population. International Scholarly Research Notices. 2014;2014:10. doi: 10.1155/2014/616271.616271 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bermúdez V., Marcano R. P., Cano C., et al. The maracaibo city metabolic syndrome prevalence study: design and scope. American Journal of Therapeutics. 2010;17(3):288–294. doi: 10.1097/mjt.0b013e3181c121bc. [DOI] [PubMed] [Google Scholar]
  • 10.Méndez H., Méndez M. Estratificación social y biología humana: método Graffar modificado. Archivos Venezolanos de Puericultura y Pediatría. 1986;49:93–104. [Google Scholar]
  • 11.Berlin I., Lin S., Lima J. A. C., Bertoni A. G. Smoking status and metabolic syndrome in the multi-ethnic study of atherosclerosis. A Cross-Sectional Study. Tobacco Induced Diseases. 2012;10(1, article 9) doi: 10.1186/1617-9625-10-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Baglietto L., English D. R., Hopper J. L., Powles J., Giles G. G. Average volume of alcohol consumed, type of beverage, drinking pattern and the risk of death from all causes. Alcohol and Alcoholism. 2006;41(6):664–671. doi: 10.1093/alcalc/agl087. [DOI] [PubMed] [Google Scholar]
  • 13.Martín Centeno A., Rojano Capilla P. Conceptos y anamnesis del consumo de alcohol en la consulta de Atención Primaria. Medicina General. 2000;29:957–962. [Google Scholar]
  • 14.Berm·dez V., Torres Y., Apruzzese V., et al. Alcohol drinking patterns in the adult population from the Maracaibo municipality, Zulia—Venezuela. Revista Latinoamericana de Hipertensión. 2014;9:21–28. [Google Scholar]
  • 15.IPAQ Core Group 2005. Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)-Short and Long Forms. 2015, https://www.researchgate.net/file.PostFileLoader.html?id=56f92d66615e27d49a658031&assetKey=AS%3A344600888791041%401459170662924.
  • 16.James P. A., Oparil S., Carter B. L., et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) The Journal of the American Medical Association. 2014;311(5):507–520. doi: 10.1001/jama.2013.284427. [DOI] [PubMed] [Google Scholar]
  • 17.World Health Organization. The World Health Report 2003. Geneva, Switzerland: World Health Organization; 2003. http://www.who.int/topics/obesity/en/ [Google Scholar]
  • 18.Health Statistics. NHANES III Reference Manuals and Reports (CDROM) Hyattsville, Md, USA: Centers for Disease Control and Prevention; 1996. http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/anthro.pdf. [Google Scholar]
  • 19.Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18(6):499–502. [PubMed] [Google Scholar]
  • 20.Alberti K. G. M. M., Eckel R. H., Grundy S. M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. doi: 10.1161/circulationaha.109.192644. [DOI] [PubMed] [Google Scholar]
  • 21.Levy J. C., Matthews D. R., Hermans M. P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191–2192. doi: 10.2337/diacare.21.12.2191. [DOI] [PubMed] [Google Scholar]
  • 22.Omran A. R. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Quarterly. 2005;83(4):731–757. doi: 10.1111/j.1468-0009.2005.00398.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ruiz-Fernández N., Espinoza M., Barrios E., Reigosa A. Factores cardiometabólicos en una comunidad de Valencia, Venezuela. Revista de Salud Pública. 2009;11:383–394. doi: 10.1590/s0124-00642009000300007. [DOI] [PubMed] [Google Scholar]
  • 24.Querales M., Rojas S., Quevedo G., Remolina J., Mundaray O., Graterol D. Cintura hipertrigliceridémica y resistencia a la insulina en una comunidad rural y una urbana de Tinaquillo. Revista Venezolana de Endocrinología y Metabolismo. 2014;12(1):25–33. [Google Scholar]
  • 25.Miguel V., Rodríguez Z., Aponte L., et al. Insulinorresistencia, obesidad y síndrome metabólico. Cohorte CDC de Canarias en Venezuela. Salus. 2013;17:18–24. [Google Scholar]
  • 26.Schargrodsky H., Hernández-Hernández R., Champagne B. M., et al. CARMELA: assessment of cardiovascular risk in seven Latin American Cities. The American Journal of Medicine. 2008;121(1):58–65. doi: 10.1016/j.amjmed.2007.08.038. [DOI] [PubMed] [Google Scholar]
  • 27.Friedrich N., Thuesen B., Jrøgensen T., et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care. 2012;35(4):768–773. doi: 10.2337/dc11-1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ziaee A., Esmailzadehha N., Oveisi S., Ghorbani A., Ghanei L. The threshold value of homeostasis model assessment for insulin resistance in Qazvin Metabolic Diseases Study (QMDS): assessment of metabolic syndrome. Journal of Research in Health Sciences. 2015;15(2):94–100. [PubMed] [Google Scholar]
  • 29.Qu H.-Q., Li Q., Rentfro A. R., Fisher-Hoch S. P., McCormick J. B. The definition of insulin resistance using HOMA-IR for americans of mexican descent using machine learning. PLoS ONE. 2011;6(6) doi: 10.1371/journal.pone.0021041.e21041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Qu H.-Q., Li Q., Lu Y., Hanis C. L., Fisher-Hoch S. P., Mccormick J. B. Ancestral effect on HOMA-IR levels quantitated in an american population of Mexican origin. Diabetes Care. 2012;35(12):2591–2593. doi: 10.2337/dc12-0636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Haffner S. M., D'Agostino R., Jr., Saad M. F., et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45(6):742–748. doi: 10.2337/diab.45.6.742. [DOI] [PubMed] [Google Scholar]
  • 32.Wallace T. M., Levy J. C., Matthews D. R. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495. doi: 10.2337/diacare.27.6.1487. [DOI] [PubMed] [Google Scholar]
  • 33.Preis S. R., Massaro J. M., Robins S. J., et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the framingham heart study. Obesity. 2010;18(11):2191–2198. doi: 10.1038/oby.2010.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Suba Z. Low estrogen exposure and/or defective estrogen signaling induces disturbances in glucose uptake and energy expenditure. Journal of Diabetes & Metabolism. 2013;4(5, article 272) doi: 10.4172/2155-6156.1000272. [DOI] [Google Scholar]
  • 35.Rojas G., Morillo Z., Salazar J., Bello L., Añez R., Varela R. Insulinorresistencia en pacientes con síndrome coronario agudo: estudio exploratorio del Hospital General del Sur de Maracaibo. Avances Cardiológicos. 2014;34:202–216. [Google Scholar]
  • 36.Rojas J., Chávez-Castillo M., Olivar L. C., et al. Physiologic course of female reproductive function: a molecular look into the prologue of life. Journal of Pregnancy. 2015;2015:21. doi: 10.1155/2015/715735.715735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.De Tata V. Age-related impairment of pancreatic beta-cell function: pathophysiological and cellular mechanisms. Frontiers in Endocrinology. 2014;5, article 138 doi: 10.3389/fendo.2014.00138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Bonora E., Formentini G., Calcaterra F., et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25(7):1135–1141. doi: 10.2337/diacare.25.7.1135. [DOI] [PubMed] [Google Scholar]
  • 39.Seidell J. C., Visscher T. L. S. Body weight and weight change and their health implications for the elderly. European Journal of Clinical Nutrition. 2000;54(3):S33–S39. doi: 10.1038/sj.ejcn.1601023. [DOI] [PubMed] [Google Scholar]
  • 40.Kalantar-Zadeh K., Streja E., Kovesdy C. P., et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clinic Proceedings. 2010;85(11):991–1001. doi: 10.4065/mcp.2010.0336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Curtis J., Selter J., Wang Y. The obesity paradox body mass index and outcomes in patients with heart failure. ACC Current Journal Review. 2005;14(4):p. 36. doi: 10.1016/j.accreview.2005.02.078. [DOI] [PubMed] [Google Scholar]
  • 42.Sobal J., Rauschenbach B. S., Frongillo E. A., Jr. Marital status, fatness and obesity. Social Science & Medicine. 1992;35(7):915–923. doi: 10.1016/0277-9536(92)90106-z. [DOI] [PubMed] [Google Scholar]
  • 43.Kiadaliri A. A., Jafari M., Vaez Mahdavi M.-R., Faghihzadeh S., Kalantari N., Asadi-Lari M. The prevalence of adulthood overweight and obesity in Tehran: findings from Urban HEART-2 study. Medical Journal of the Islamic Republic of Iran. 2015;29, article 178 [PMC free article] [PubMed] [Google Scholar]
  • 44.Arem H., Moore S. C., Patel A., et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Internal Medicine. 2015;175(6):959–967. doi: 10.1001/jamainternmed.2015.0533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Nelson R. K., Horowitz J. F., Holleman R. G., et al. Daily physical activity predicts degree of insulin resistance: a cross-sectional observational study using the 2003-2004 National Health and Nutrition Examination Survey. International Journal of Behavioral Nutrition and Physical Activity. 2013;10, article 10 doi: 10.1186/1479-5868-10-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Standards of medical care in diabetes—2015: summary of revisions. Diabetes Care. 2015;38(supplement 1, article S4) doi: 10.2337/dc15-S003. [DOI] [PubMed] [Google Scholar]
  • 47.Bendsen N. T., Christensen R., Bartels E. M., et al. Is beer consumption related to measures of abdominal and general obesity? A systematic review and meta-analysis. Nutrition Reviews. 2013;71(2):67–87. doi: 10.1111/j.1753-4887.2012.00548.x. [DOI] [PubMed] [Google Scholar]
  • 48.Carnethon M. R., Fortmann S. P., Palaniappan L., Duncan B. B., Schmidt M. I., Chambless L. E. Risk factors for progression to incident hyperinsulinemia: The Atherosclerosis Risk in Communities Study, 1987–1998. American Journal of Epidemiology. 2003;158(11):1058–1067. doi: 10.1093/aje/kwg260. [DOI] [PubMed] [Google Scholar]
  • 49.Furler S. M., Poynten A. M., Kriketos A. D., et al. Independent influences of central fat and skeletal muscle lipids on insulin sensitivity. Obesity Research. 2001;9(9):535–543. doi: 10.1038/oby.2001.70. [DOI] [PubMed] [Google Scholar]
  • 50.Hoffman R. P. Increased fasting triglyceride levels are associated with hepatic insulin resistance in caucasian but not African-American adolescents. Diabetes Care. 2006;29(6):1402–1404. doi: 10.2337/dc06-2460. [DOI] [PubMed] [Google Scholar]
  • 51.Laws A., Reaven G. M. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. Journal of Internal Medicine. 1992;231(1):25–30. doi: 10.1111/j.1365-2796.1992.tb00494.x. [DOI] [PubMed] [Google Scholar]
  • 52.deCarvalho M. H., Colaço A. L., Fortes Z. B. Citocinas, disfunção endotelial e resistência à insulina. Arquivos Brasileiros de Endocrinologia & Metabologia. 2006;50(2):304–312. doi: 10.1590/s0004-27302006000200016. [DOI] [PubMed] [Google Scholar]
  • 53.Muoio D. M., Newgard C. B. Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nature Reviews Molecular Cell Biology. 2008;9(3):193–205. doi: 10.1038/nrm2327. [DOI] [PubMed] [Google Scholar]
  • 54.Castillo-Nuñez Y., Aguilar-Salina C. A. Medición de la resistencia a la insulina en la práctica clínica. Revista ALAD. 2015;5:8–10. [Google Scholar]

Articles from Advances in Preventive Medicine are provided here courtesy of Wiley

RESOURCES